Tango Therapeutics Inc (TNGX)
3.92
+0.36
(+10.11%)
USD |
NASDAQ |
Nov 14, 16:00
3.90
-0.02
(-0.51%)
After-Hours: 20:00
Tango Therapeutics Enterprise Value: 89.13M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 89.13M |
| November 12, 2024 | 66.57M |
| November 11, 2024 | 69.79M |
| November 08, 2024 | 23.60M |
| November 07, 2024 | 10.71M |
| November 06, 2024 | 54.76M |
| November 05, 2024 | 263.15M |
| November 04, 2024 | 261.00M |
| November 01, 2024 | 259.92M |
| October 31, 2024 | 290.52M |
| October 30, 2024 | 320.06M |
| October 29, 2024 | 351.21M |
| October 28, 2024 | 342.62M |
| October 25, 2024 | 343.69M |
| October 24, 2024 | 382.36M |
| October 23, 2024 | 380.21M |
| October 22, 2024 | 419.95M |
| October 21, 2024 | 474.74M |
| October 18, 2024 | 508.03M |
| October 17, 2024 | 458.62M |
| October 16, 2024 | 473.66M |
| October 15, 2024 | 448.96M |
| October 14, 2024 | 441.44M |
| October 11, 2024 | 443.59M |
| October 10, 2024 | 410.29M |
| Date | Value |
|---|---|
| October 09, 2024 | 434.99M |
| October 08, 2024 | 446.81M |
| October 07, 2024 | 457.55M |
| October 04, 2024 | 456.48M |
| October 03, 2024 | 447.88M |
| October 02, 2024 | 462.92M |
| October 01, 2024 | 488.70M |
| September 30, 2024 | 533.81M |
| September 27, 2024 | 478.26M |
| September 26, 2024 | 466.47M |
| September 25, 2024 | 473.97M |
| September 24, 2024 | 476.12M |
| September 23, 2024 | 501.83M |
| September 20, 2024 | 567.19M |
| September 19, 2024 | 578.97M |
| September 18, 2024 | 565.05M |
| September 17, 2024 | 601.47M |
| September 16, 2024 | 707.55M |
| September 13, 2024 | 802.91M |
| September 12, 2024 | 749.33M |
| September 11, 2024 | 716.12M |
| September 10, 2024 | 651.83M |
| September 09, 2024 | 659.33M |
| September 06, 2024 | 844.69M |
| September 05, 2024 | 929.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-130.14M
Minimum
Sep 26 2022
1.323B
Maximum
Sep 17 2021
360.94M
Average
344.56M
Median
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.762M |
| Palatin Technologies Inc | 13.74M |
| iBio Inc | 6.814M |
| Theriva Biologics Inc | -13.26M |
| Oragenics Inc | 2.142M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -29.17M |
| Revenue (Quarterly) | 11.61M |
| Total Expenses (Quarterly) | 44.48M |
| EPS Diluted (Quarterly) | -0.27 |
| Profit Margin (Quarterly) | -251.3% |
| Earnings Yield | -29.74% |
| Normalized Earnings Yield | -29.74 |